<DOC>
	<DOCNO>NCT00729664</DOCNO>
	<brief_summary>Collection survival data , evaluation PDL-1 expression tumor , evaluation PD-L1 receptor occupancy peripheral blood add .</brief_summary>
	<brief_title>Multiple Ascending Dose ( MDX1105-01 )</brief_title>
	<detailed_description>This open label , multicenter , dose escalation multidose study MDX-11-5 , fully human monoclonal IgG4 antibody target Programed Death-Ligand 1 ( PD-L1 ) . The study consist 3 period : Screening ( 28 day ) , Treatment ( 16 six-week cycle ) , Follow-up ( 6 month ) .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 The malignancy include relapsed/refractory renal cell carcinoma , nonsmall cell lung cancer , colorectal adenocarcinoma , malignant melanoma , advanced/metastatic epithelial ovarian cancer , gastric cancer , pancreatic cancer breastcancer Must measurable disease Prior therapy antiPD 1 , antiPDL 1 , antiCytotoxic TLymphocyte Antigen 4 antibody ( agent target Tcell costimulation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>